SCHEMBL31408327

SCHEMBL31408327

COc1cnc(-c2cc3[nH]c(CNC(=O)N4CCC(O)C4)cc3cc2Cl)cn1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 2/20 0.35
▸ PRKAB2 O43741 4/20 0.35
▸ PRKAG1 P54619 4/20 0.35
▸ PRKAA2 P54646 4/20 0.35
▸ PRKAA1 Q13131 4/20 0.35
▸ PRKAG3 Q9UGI9 4/20 0.35
▸ PRKAG2 Q9UGJ0 4/20 0.35
▸ PRKAB1 Q9Y478 4/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ PDCD1 Q15116 4/20 0.33
▸ CD274 Q9NZQ7 4/20 0.33
▸ MAPK1 P28482 2/20 0.33
▸ CYP51A1 Q16850 1/20 0.33
▸ JUN P05412 1/20 0.33
▸ CDK2 P24941 1/20 0.33
▸ MAPK8 P45983 1/20 0.33
▸ MAPK9 P45984 1/20 0.33
▸ MAPK10 P53779 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31408429 1.00 LRRK2 (0.35) LRRK2PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL31408237 1.00 LRRK2 (0.35) LRRK2PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL31408537 0.93 SMN1; SMN2 (0.36) LRRK2SMN1; SMN2PDCD1CD274MAPK1
SCHEMBL31408430 0.88 MAPK1 (0.37) SMN1; SMN2MAPK1CYP2C9CYP2C19EPHX2
SCHEMBL31408279 0.87 SMN1; SMN2 (0.36) LRRK2SMN1; SMN2MAPK1
SCHEMBL31408356 0.86 POLB (0.39) LRRK2SMN1; SMN2MAPK1
SCHEMBL31408437 0.85 SMN1; SMN2 (0.34) LRRK2SMN1; SMN2PDCD1CD274MAPK1
SCHEMBL31408514 0.85 SMN1; SMN2 (0.36) SMN1; SMN2PDCD1CD274MAPK1EPHX2
SCHEMBL31408404 0.84 LRRK2 (0.36) LRRK2SMN1; SMN2PDCD1CD274MAPK1
SCHEMBL31408376 0.83 JAK2 (0.40) CCNT1JAK2JAK3PTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025049604-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2025-03-06 — — WO disclosed
Send feedback